This research demonstrates significant photocatalytic degradation of ciprofloxacin using Co²⁺-doped materials and persulfate activation.
Pharmaceutical residues, particularly ciprofloxacin (CIP), are frequently detected in aquatic environments and pose significant risks to ecosystems and human health. This study investigates the visible-light photocatalytic degradation of CIP using Co²⁺-modified Zn₀.₆₆₇Al₀.₃₃₃-layered double hydroxide (LDH) materials, with persulfate (PS) as a co-activator. The hydrotalcite-like compounds Zn₀.₆₆₇Al₀.₃₃₃(OH)₂(CO₃)₀.₁₆₇•0.5H₂O, denoted as nCoZnH, were synthesized by co-precipitation.These were further calcined at 500 °C for 5 hours to obtain nCoZnH500. Both uncalcined and calcined materials were characterized structurally and physicochemically. Results revealed that nCoZnH maintained the typical hydrotalcite layered structure, with Co²⁺ ions effectively incorporated into brucite-like layers through isomorphic substitution of Zn²⁺. Upon calcination, partial retention of the LDH structure was observed, accompanied by the formation of ZnO and Co₃O₄ phases. The BET surface area of nCoZnH500 was markedly higher than that of uncalcined counterparts. Co²⁺ modification also significantly reduced the bandgap energy, thereby enhancing visible-light-induced photocatalytic activity. Among all samples, 1.0CoZnH and 2.0CoZnH500 exhibited the highest degradation efficiencies, 78.0 ± 1.87% and 70.9 ± 2.31%, respectively, for 10 ppm CIP under visible light. Furthermore, the photocatalytic activity of the synthesized materials was influenced by the Co: Al molar ratio, initial CIP concentration, persulfate (S₂O₈²⁻) dosage, and solution pH. The 2.0CoZnH500 sample demonstrated superior stability compared to 1.0CoZnH, with only a 9.1% reduction in the CIP removal efficiency after four consecutive cycles, maintaining a degradation efficiency of 59.7%. These findings indicate that the synergy between Co²⁺ doping and PS activation effectively boosts CIP degradation. The developed materials offer promising potential for the treatment of pharmaceutical wastewater under visible light irradiation.
No takes yet. Share an insight, caveat, or question.
Vu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: